| Identification | Back Directory | [Name]
Antitumor agent-19 | [CAS]
2379727-90-7 | [Synonyms]
Antitumor agent-19
Antitumor agent 19,Antitumor agent19
Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[2,3,4,9-tetrahydro-5-(1-methyl-1H-pyrazol-4-yl)-1H-carbazol-3-yl]- | [Molecular Formula]
C24H21ClF3N5O | [MDL Number]
MFCD32263033 | [MOL File]
2379727-90-7.mol | [Molecular Weight]
487.9 |
| Hazard Information | Back Directory | [Uses]
Antitumor agent-19 is an antitumor agent that targets tumor-associated macrophages (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC50 values???of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively[1]. | [in vivo]
Antitumor agent-19 (Compound 23a; 5 mg/kg; intraperitoneal injection; every other day; for 30 days; C57BL/6 female mice) is capable of remarkably inhibiting tumor growth of the LLC mouse model. Moreover, the synergy of Antitumor agent-19 with anti-PD-1 antibody has more superior antineoplastic effects than the exclusive use of either in vivo[1]. | Animal Model: | Six-to eight-week-old C57BL/6 female mice with lewis lung cancer cells (LLC)[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection; every other day; for 30 days | | Result: | Remarkably inhibited tumor growth of the LLC mouse model.
|
| [References]
[1] Pei H, et al. iscovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. Eur J Med Chem. 2019 Sep 28;183:111741. DOI:10.1016/j.ejmech.2019.111741 |
|
|